{"id":"conbercept-ophthalmic-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Intraocular pressure elevation"},{"rate":null,"effect":"Endophthalmitis"}]},"_chembl":{"chemblId":"CHEMBL2108313","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Conbercept functions as a VEGF/PlGF trap by combining the extracellular domains of VEGF receptors 1 and 2 fused to the Fc region of human immunoglobulin G1. This construct has higher binding affinity for VEGF and PlGF compared to bevacizumab and ranibizumab, allowing it to more effectively suppress abnormal blood vessel growth and vascular permeability in retinal diseases. By blocking these pro-angiogenic pathways, it reduces vision loss and retinal edema associated with age-related macular degeneration and diabetic retinopathy.","oneSentence":"Conbercept is a recombinant fusion protein that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit pathological neovascularization in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:22.613Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular age-related macular degeneration (wet AMD)"},{"name":"Diabetic macular edema (DME)"},{"name":"Retinal vein occlusion (RVO)"}]},"trialDetails":[{"nctId":"NCT07144865","phase":"NA","title":"Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection","status":"COMPLETED","sponsor":"Bojie Hu","startDate":"2024-12-01","conditions":"Proliferative Diabetic Retinopathy","enrollment":8},{"nctId":"NCT07106268","phase":"","title":"Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2023-03-01","conditions":"Retinal Vein Occlusion","enrollment":100},{"nctId":"NCT06717412","phase":"NA","title":"Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy","status":"RECRUITING","sponsor":"Wang Yusheng","startDate":"2024-11-29","conditions":"Retinopathy of Prematurity (ROP)","enrollment":146},{"nctId":"NCT04782115","phase":"PHASE2","title":"Evaluation of RC28-E Injection in Diabetic Macular Edema","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2021-03-17","conditions":"Diabetic Macular Edema","enrollment":156},{"nctId":"NCT04985448","phase":"","title":"Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2022-09","conditions":"Retinopathy of Prematurity","enrollment":1000},{"nctId":"NCT03108352","phase":"PHASE3","title":"Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2016-04-13","conditions":"Branch Retinal Vein Occlusion, Macular Edema","enrollment":255},{"nctId":"NCT03223714","phase":"PHASE3","title":"Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2016-05-24","conditions":"Macular Edema, Central Retinal Vein Occlusion","enrollment":242},{"nctId":"NCT04990271","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2021-07-05","conditions":"Retinoblastoma","enrollment":92},{"nctId":"NCT03577899","phase":"PHASE3","title":"Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)","status":"TERMINATED","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2018-09-25","conditions":"Neovascular Age-related Macular Degeneration","enrollment":1157},{"nctId":"NCT03630952","phase":"PHASE3","title":"Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)","status":"TERMINATED","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2018-12-21","conditions":"Neovascular Age-related Macular Degeneration","enrollment":1157},{"nctId":"NCT02911311","phase":"NA","title":"Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-10-12","conditions":"Proliferative Diabetic Retinopathy","enrollment":226},{"nctId":"NCT04668703","phase":"NA","title":"Prophylactic Effect of Conbercept Intravitreal Injection at the Conclusion of Cataract Surgery for Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2021-01-01","conditions":"Diabetic Macular Edema, Diabetic Retinopathy, Cataract Diabetic","enrollment":40},{"nctId":"NCT03244657","phase":"PHASE4","title":"Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2017-04-25","conditions":"Polypoid Choroidal Vasculopathy (PCV)","enrollment":200},{"nctId":"NCT03159884","phase":"PHASE4","title":"The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2015-10","conditions":"Polypoidal Choroidal Vasculopathy (PCV)","enrollment":300},{"nctId":"NCT03054818","phase":"","title":"Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word（STONE）","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2016-10","conditions":"Wet Age-related Macular Degeneration (wAMD)","enrollment":4000},{"nctId":"NCT02098720","phase":"PHASE2","title":"An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2011-12","conditions":"Very Low Vision Secondary to Wet Age-related Macular Degeneration","enrollment":30},{"nctId":"NCT01809223","phase":"PHASE3","title":"A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV","status":"UNKNOWN","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2012-08","conditions":"Choroid Neovascularization Secondary to Degenerative Myopia","enrollment":176}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":173,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["KH902"],"phase":"phase_3","status":"active","brandName":"Conbercept ophthalmic injection","genericName":"Conbercept ophthalmic injection","companyName":"Chengdu Kanghong Biotech Co., Ltd.","companyId":"chengdu-kanghong-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Conbercept ophthalmic injection is a vascular endothelial growth factor A inhibitor used to treat various eye conditions, including macular edema, central retinal vein occlusion, polypoid choroidal vasculopathy, choroid neovascularization secondary to degenerative myopia, and retinal vein occlusion. It is administered via intravitreal injection in the form of a 0.5mg dose.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}